ASCENTAGE Plans ATM Offering of ADSs in US to Raise Up to USD200 million
I'm LongbridgeAI, I can summarize articles.ASCENTAGEannounced the submission of a Form F-3 registration statement for an at-the-market (ATM) offering program to sell up to USD200 million in American Depositary Shares (ADSs) on Nasdaq. The net proceeds will fund commercialization and clinical trials for olverembatinib and lisaftoclax, working capital, general corporate purposes, or investments in complementary businesses.
ASCENTAGE (06855.HK) 0.000 (0.000%) Short selling $43.37M; Ratio 27.945% announced that it submitted an automatic shelf registration statement on Form F-3 to the U.S. Securities and Exchange Commission on July 20, U.S. Eastern Time, for a proposed at-the-market offering program (ATM Program). Under the program, the company may sell American Depositary Shares (ADSs) with an aggregate offering price of up to USD200 million on Nasdaq from time to time through sales agents. Each ADS represents four ordinary shares and may be sold at prevailing market prices, related prices or negotiated prices. Sales may be conducted through ordinary brokerage transactions on Nasdaq, over-the-counter transactions or negotiated transactions, and will adopt two execution strategies, namely gradual sales and block trades as agent.
The net proceeds are intended to be used for the commercialization and clinical trials of olverembatinib and lisaftoclax, working capital and general corporate purposes, or investments in complementary businesses and technologies. (gc/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-17 16:25.)